Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Active not recruiting 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 280Thoracic 15Gastrointestinal 11Gynecologic 7Other 4Genitourinary 3Dermatologic 3CNS 3Breast 3Other neoplasm 2Sarcoma 1Classical hematology 1

Conditions

Melanoma 36Carcinoma, Non-Small-Cell Lung 8Neoplasms 6Colorectal Neoplasms 6Carcinoma, Renal Cell 5Breast Neoplasms 5Stomach Neoplasms 4Neoplasm Metastasis 4Lymphoma, Follicular 4Uveal Melanoma 3Squamous Cell Carcinoma of Head and Neck 3Skin Neoplasms 3Prostatic Neoplasms 3Ovarian Neoplasms 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Non-Hodgkin 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Carcinoma, Ovarian Epithelial 3Carcinoma, Merkel Cell 3Thyroid Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2

Interventions

pembrolizumab 59Nivolumab 19atezolizumab 8Ipilimumab 8Docetaxel 7avelumab 6Paclitaxel 6cemiplimab 5Specimen Handling 5Cyclophosphamide 5Biopsy 5Taxes 4Pemetrexed 4Magnetic Resonance Spectroscopy 4Interleukin-2 4Gemcitabine 4Carboplatin 4utomilumab 3epacadostat 3durvalumab 3Radiotherapy 3Cisplatin 3Cetuximab 3tremelimumab 2tislelizumab 2sargramostim 2poly ICLC 2obinutuzumab 2fludarabine 2enzalutamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × Cisplatin × Dermatologic × Clear all
NCT03645928 2026-05-15

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Iovance Biotherapeutics, Inc.

Phase 2 Terminated
225 enrolled
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04083599 2026-05-06

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Genmab

Phase 1/2 Active not recruiting
350 enrolled
DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Inhibrx Biosciences, Inc

Phase 1/2 Active not recruiting
296 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡